2022
DOI: 10.14309/ajg.0000000000001702
|View full text |Cite
|
Sign up to set email alerts
|

Additional Analyses for the Published Primary Norfloxacin Prophylaxis for APASL-Defined Acute-on-Chronic Liver Failure

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 2 publications
0
1
0
Order By: Relevance
“… 9 A recent trial of primary norfloxacin prophylaxis effectively prevents bacterial infections in patients with ACLF that recruited 172 patients in India. 67 Mortality also significantly improved in the treatment arm, 68 but more patients developed candiduria in the norfloxacin group. In contrast, the AntibioCor study of 284 patients with severe alcohol-associated hepatitis showed that the addition of amoxicillin/clavulanate to prednisolone reduced infection rates but did not extend survival and the authors do not recommend prophylaxis for these patients.…”
Section: Other (Potential) Indicationsmentioning
confidence: 91%
“… 9 A recent trial of primary norfloxacin prophylaxis effectively prevents bacterial infections in patients with ACLF that recruited 172 patients in India. 67 Mortality also significantly improved in the treatment arm, 68 but more patients developed candiduria in the norfloxacin group. In contrast, the AntibioCor study of 284 patients with severe alcohol-associated hepatitis showed that the addition of amoxicillin/clavulanate to prednisolone reduced infection rates but did not extend survival and the authors do not recommend prophylaxis for these patients.…”
Section: Other (Potential) Indicationsmentioning
confidence: 91%